205 related articles for article (PubMed ID: 19609054)
21. Impact of the therapy by renin-angiotensin system targeting antihypertensive agents perindopril versus telmisartan on prothrombotic state in essential hypertension.
Remková A; Kratochvíl'ová H; Durina J
J Hum Hypertens; 2008 May; 22(5):338-45. PubMed ID: 18305548
[TBL] [Abstract][Full Text] [Related]
22. Rationale for double renin-angiotensin-aldosterone system blockade.
Unger T; Stoppelhaar M
Am J Cardiol; 2007 Aug; 100(3A):25J-31J. PubMed ID: 17666194
[TBL] [Abstract][Full Text] [Related]
23. Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients.
Usui I; Fujisaka S; Yamazaki K; Takano A; Murakami S; Yamazaki Y; Urakaze M; Hachiya H; Takata M; Senda S; Iwata M; Satoh A; Sasaoka T; Ak ND; Temaru R; Kobayashi M
Diabetes Res Clin Pract; 2007 Aug; 77(2):210-4. PubMed ID: 17240472
[TBL] [Abstract][Full Text] [Related]
24. Long-term effects of telmisartan on blood pressure, the renin-angiotensin-aldosterone system, and lipids in hypertensive patients.
Aoki A; Ogawa T; Sumino H; Kumakura H; Takayama Y; Ichikawa S; Nitta K
Heart Vessels; 2010 May; 25(3):195-202. PubMed ID: 20512446
[TBL] [Abstract][Full Text] [Related]
25. Telmisartan decreases plasma levels of asymmetrical dimethyl-L-arginine and improves lipid and glucose metabolism and vascular function.
Ono Y; Nakaya Y; Bando S; Soeki T; Ito S; Sata M
Int Heart J; 2009 Jan; 50(1):73-83. PubMed ID: 19246848
[TBL] [Abstract][Full Text] [Related]
26. Recent advances in cardiovascular risk reduction: implications of ONTARGET.
Guthrie R
Clin Cornerstone; 2009; 9 Suppl 3():S18-26. PubMed ID: 19409352
[TBL] [Abstract][Full Text] [Related]
27. Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension.
Nedogoda SV; Ledyaeva AA; Chumachok EV; Tsoma VV; Mazina G; Salasyuk AS; Barykina IN
Clin Drug Investig; 2013 Aug; 33(8):553-61. PubMed ID: 23800977
[TBL] [Abstract][Full Text] [Related]
28. Alterations of insulin resistance and the serum adiponectin level in patients with type 2 diabetes mellitus under the usual antihypertensive dosage of telmisartan treatment.
Fuke Y; Fujita T; Satomura A; Wada Y; Matsumoto K
Diabetes Technol Ther; 2010 May; 12(5):393-8. PubMed ID: 20388049
[TBL] [Abstract][Full Text] [Related]
29. Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome.
Bahadir O; Uzunlulu M; Oguz A; Bahadir MA
Hypertens Res; 2007 Jan; 30(1):49-53. PubMed ID: 17460371
[TBL] [Abstract][Full Text] [Related]
30. Short-term dietary salt supplementation blunts telmisartan induced increases in plasma renin activity in hypertensive patients with type 2 diabetes mellitus.
Chen AX; Jerums G; Baqar S; Lambert E; Somarajah G; Thomas G; O'Callaghan C; MacIsaac RJ; Ekinci EI
Clin Sci (Lond); 2015 Sep; 129(5):415-22. PubMed ID: 25849646
[TBL] [Abstract][Full Text] [Related]
31. Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril.
Smith DH
Clin Ther; 2002 Oct; 24(10):1484-501. PubMed ID: 12462282
[TBL] [Abstract][Full Text] [Related]
32. Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro.
Yamada S; Ano N; Toda K; Kitaoka A; Shiono K; Inoue G; Atsuda K; Irie J
Hypertens Res; 2008 Apr; 31(4):601-6. PubMed ID: 18633170
[TBL] [Abstract][Full Text] [Related]
33. Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE study.
Ragot S; Ezzaher A; Meunier A; Poterre M; Bourkaib R; Herpin D
J Hum Hypertens; 2002 Dec; 16(12):865-73. PubMed ID: 12522468
[TBL] [Abstract][Full Text] [Related]
34. Perindopril for improving cardiovascular events.
DiNicolantonio JJ; O'Keefe JH
Vasc Health Risk Manag; 2014; 10():539-48. PubMed ID: 25210459
[No Abstract] [Full Text] [Related]
35. Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients.
Watanabe M; Inukai K; Sumita T; Ikebukuro K; Ito D; Kurihara S; Ono H; Awata T; Katayama S
Intern Med; 2010; 49(17):1843-7. PubMed ID: 20823643
[TBL] [Abstract][Full Text] [Related]
36. Microalbuminuria and hypertension in HIV-infected patients: a preliminary study of telmisartan.
Ucciferri C; Falasca K; Mancino P; Di Iorio A; Vecchiet J
Eur Rev Med Pharmacol Sci; 2012 Apr; 16(4):491-8. PubMed ID: 22696876
[TBL] [Abstract][Full Text] [Related]
37. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
Schindler C
Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
[TBL] [Abstract][Full Text] [Related]
38. Telmisartan and cardioprotection.
Akhrass PR; McFarlane SI
Vasc Health Risk Manag; 2011; 7():677-83. PubMed ID: 22140319
[TBL] [Abstract][Full Text] [Related]
39. Telmisartan at 80 mg/day increases high-molecular-weight adiponectin levels and improves insulin resistance in diabetic patients.
Mori H; Okada Y; Arao T; Nishida K; Tanaka Y
Adv Ther; 2012 Jul; 29(7):635-44. PubMed ID: 22821644
[TBL] [Abstract][Full Text] [Related]
40. Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients.
Petrovic I; Petrovic D; Vukovic N; Zivanovic B; Dragicevic J; Vasiljevic Z; Babic R
J Int Med Res; 2005; 33 Suppl 1():39A-49A. PubMed ID: 16222899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
